Evidence of Cellular Immune Activation in Children With Opsoclonus-Myoclonus: Cerebrospinal Fluid Neopterin

Abstract

To evaluate cellular immune activation in opsoclonus-myoclonus syndrome, we measured the inflammatory marker neopterin in the cerebrospinal fluid of 16 children with opsoclonus-myoclonus and neuroblastoma, 24 children with opsoclonus-myoclonus but no tumor, and 19 age-matched controls. The mean concentration in opsoclonus-myoclonus was 2.3-fold higher than in controls (P = .008). Neopterin was greatly elevated in four of the most neurologically severe cases, up to 8.3-fold above the highest control level. Thirteen of the 40 children with opsoclonus-myoclonus but no controls had a neopterin concentration > 2 SD above the control mean (P = .005). In this high neopterin subgroup, neurologic severity was significantly greater and the duration of neurologic symptoms was less. In 16 children re-examined on immunotherapy, including adrenocorticotropic hormone (ACTH) combination therapy, treatment was associated with a significant reduction in both neopterin and neurologic severity. Neopterin did not differ significantly between the tumor and non-tumor opsoclonus-myoclonus etiologies. No abnormalities of tetrahydrobiopterin were found. Although cerebrospinal fluid neopterin lacked the sensitivity to be a biomarker of disease activity in opsoclonus-myoclonus, elevated concentrations do support a role for T-cell activation and cell-mediated immunity in its pathophysiology. (J Child Neurol 2004;19:919—924).

Get full access to this article

View all access options for this article.

References

Kinsbourne M. : Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry 1962;25:221—276.

Solomon GE , Chutorian AM : Opsoclonus and occult neuroblastoma. N Engl J Med 1968;279:475—477.

Nishihara H. , Toyoda Y. , Tanaka Y. , et al: Natural course of neuroblastoma detected by mass screening: A 5-year prospective study at a single institution. J Clin Oncol 2000;18:3012—3017.

Pranzatelli MR : The immunopharmacology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 1996;19:1—47.

Gennery AJ , Cant A. , Forsyth RJ : Development of parainfectious opsoclonus in an infant by a non-humoral immune mechanism. Dev Med Child Neurol 2001;43:213—216.

Huber C. , Fuchs D. , Hausen A. , et al: Pteridines as a new marker to detect human T cells activated by allogeneic or modified self m a j o r h i s t o c o m p a t i b i l i t y c o m p l e x (M H C) d e t e r m i n a n t s . J Immunol 1983; 130: 1047—1050.

Ziegler J. , Hamm U. , Berndt J. : Participation of pterins in the control of lymphocyte stimulation and lymphoblast proliferation. Cancer Res 1983;43:5356—5359.

Fuchs D. , Weiss G. , Reibnegger G. , Wachter H. : The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant disease. Crit Rev Clin Lab Sci 1992;29:307—341.

Wachter H. , Fuchs D. , Hausen A. , et al: Neopterin as a marker for activation of cellular immunity: Immunological basis and clinical application. Adv Clin Chem 1989;27:81—141.

10.

Millner MM , Franthal W. , Thalhammer GH , et al: Neopterin concentrations in cerebrospinal fluid and serum as an aid in differentiating central nervous system and peripheral infections in children. Clin Chem 1998;44:161—167.

11.

Kern P. , Rokos H. , Dietrich M. : Raised serum neopterin levels and imbalance of T lymphocyte subsets in viral diseases, acquired immunodeficiency and related lymphadenopathy syndrome. Biomed Pharmacother 1984;38:407—411.

12.

Howells DW , Smith I. , Hyland K. : Dihydroneopterin and CNS infections. Lancet 1987;ii:686—687.

13.

Tate ED , Pranzatelli MR , Huang YY , Kaplan R. : An innovative approach to the problem of sedating children with opsoclonus-myoclonus syndrome: Effects on myoclonus and CSF monoamine metabolites, abstract. Ann Neurol 1994;36:543—544.

14.

Howells, DW , Smith I. , Hyland K. : Estimation of tetrahydrobiopterin and other pterins in cerebrospinal fluid using reverse-phase high performance liquid chromatography. J Chromatogr 1986;381: 285—294.

15.

Pranzatelli MR , Tate ED , Galvan I. , Wheeler A. : A controlled pilot study of piracetam for pediatric opsoclonus-myoclonus. Clin Neuropharmacol 2001;24:352—357.

16.

Pranzatelli MR , Huang Y. , Tate E. , et al: Effect of high dose corticotropin on cerebrospinal fluid monoaminergic neurotransmitters or metabolites in corticotropin-responsive pediatric opsoclonus-myoclonus. Mov Disord 1998;13:522—528.

17.

SAS Institute Inc. : SAS/STAT User's Guide, Version 8.2. Cary, NC, SAS Institute Inc., 2002.

18.

Furukawa Y. , Nishi K. , Kondo T. , et al: Significance of CSF total neopterin and biopterin in inflammatory neurological diseases. J Neurol Sci 1992; 111:65-72.

19.

Hyland K. , Surtees Rah , Heales Sjh , et al: Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population. Pediatr Res 1993;34:10—14.

20.

Zaknun D. , Zaknun J. , Unsinn K. , et al: Interferon gamma-induced formation of neopterin and degradation of tryptophan in cerebrospinal fluid of children with meningitis but not with febrile convulsions. Pteridines 1994;5:102—106.

21.

Hagberg L. : The clinical use of cerebrospinal fluid neopterin concentrations in central nervous system infections. Pteridines 1996 ;6:147—152.

22.

Pranzatelli MR , Travelstead A. , Tate ED , et al: B and T cell markers in pediatric opsoclonus-myoclonus-ataxia: Immunophenotyping of CSF and blood lymphocytes by flow cytometry, abstract. Ann Neurol 2002 ;52(Suppl 1):S123.

23.

Pranzatelli MR , Huang Y. , Tate E. , et al: Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in the pediatric opsoclonus-myoclonus syndrome . Ann Neurol 1995;37:189—197.